Aviton

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aviton

Quick Facts

Property Description
Active Ingredients Ferrous Fumarate, Folic Acid, Cyanocobalamin, Zinc Sulphate, Copper Sulphate, Manganese Sulphate, L-lysine Monohydrochloride
Form Tablet, Capsule, Syrup (Oral Use)
Pharmacological Class Nutritional and Hematopoietic Agents
General Purpose Counteracting Nutritional Deficiencies, Blood and Energy Support
Origin/Type Synthetic and Derived Combination

Aviton: Identity and Pharmacological Classification

Aviton is a specialized, multi-component formula classified pharmacologically as a Nutritional and Hematopoietic Agent, designed for administration via the oral route as a dietary supplement. It serves as a foundational Essential Nutrient Supplement, distinguished by its robust, fixed-dose combination of seven active ingredients. Pharmacological studies have clinically recognized formulations containing key B-vitamins and iron for their role in promoting healthy red blood cell and hemoglobin synthesis. This preparation provides a highly targeted approach compared to simple multivitamins, focusing specifically on supporting the processes necessary to maintain energy levels and prevent deficiencies that contribute to generalized weakness.

What is the Composition of Aviton?

Aviton is composed of seven distinct active ingredients, which include four essential minerals, two key B-complex vitamins, and a single amino acid. The minerals are Ferrous Fumarate (the source of elemental iron), Zinc Sulphate, Copper Sulphate, and Manganese Sulphate; the vitamins are Folic Acid (Vitamin B9) and Cyanocobalamin (Vitamin B12); and the essential amino acid is L-lysine Monohydrochloride. The components are predominantly synthetic and derived, combined into various dosage forms, such as tablets, capsules, or syrup, suitable for oral use. This blend is often marketed towards a broad patient group, including those needing comprehensive pregnancy support or recovery from extended illness.

General Purpose and High-Level Benefit

The general benefit of Aviton is to counteract nutritional gaps by supplying the necessary building blocks for healthy bodily function, primarily focusing on blood and energy support. This structured combination aims to support the body's natural capacity for red blood cell production and ensures sufficient availability of cofactors necessary for fundamental cellular metabolism and nerve function. The formulation is specifically designed to offer greater amounts of key hematopoietic elements than standard general wellness supplements, which is crucial for individuals with specific, verified deficiencies. By providing simultaneous replenishment of these critical components, Aviton aids in relieving the generalized symptoms of weakness and fatigue often associated with these underlying deficiencies.

Regulatory References

  1. NIH: National Library of Medicine

What side effects are possible with Aviton?

Possible Side Effects and Safety Information

This section describes the possible side effects and safety characteristics of the Aviton formulation as documented in official government regulatory documents.

Adverse effects are primarily classified into two system-organ groups: Gastrointestinal Disorders and Immune System Disorders. Gastrointestinal disturbances are frequently listed as the most common group of adverse effects. These include nausea, vomiting, constipation, diarrhea, epigastric pain, and abdominal distension. The appearance of dark or black stools is an expected, non-harmful consequence associated with the iron component.

Classification Adverse Reactions (Examples from Regulatory Labels)
Rare Severe allergic responses, including anaphylactic reactions or anaphylactic shock.
Common/Occasional Gastrointestinal disturbances (e.g., nausea, constipation, diarrhea).

Serious Adverse Reactions documented in regulatory sources include the critical risk of fatal poisoning in children under six from accidental iron overdose. Additionally, there is a risk of progression of subacute combined degeneration of the spinal cord if the Folic Acid component is inappropriately administered to individuals with undiagnosed Vitamin B12 deficiency.

Official labeling mandates specific safety constraints. Iron-containing tablets must be swallowed whole and not sucked or chewed, due to the regulatory risk of mucosal ulceration. The safety profile is also defined by population-specific restrictions, such as warnings that constipation may occur with continual administration, particularly in older patients, and contraindications for individuals with pre-existing conditions like hemochromatosis or active peptic ulcer.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Manifestations and Scope

Acute Aviton overdose is primarily driven by the documented toxicity profile of its iron component, Ferrous Fumarate. The risk of severe or fatal poisoning is especially high in young children. Documented presentations initially involve severe gastrointestinal effects, including nausea, vomiting, diarrhea, and significant abdominal pain, which may progress to involve vomiting blood (hematemesis). Physiological systems affected include the Gastrointestinal System, Cardiovascular System, Metabolic System, and Hepatic System. Later signs documented in regulatory warnings include pallor, lethargy, and hypotension.

Immediate Emergency Action and Severe Outcomes

Regulatory guidance classifies an overdose as potentially severe and life-threatening. Emergency-response statements mandate that individuals SEEK IMMEDIATE MEDICAL ATTENTION and contact emergency services or a Poison Control Center immediately upon any suspicion of overdose. This urgent action is required due to the documented risk of progression to systemic toxicity, including circulatory collapse, metabolic acidosis, and severe organ damage such as hepatic necrosis and renal failure.

Required Management and Monitoring

Hospital monitoring and continuous supportive treatment are officially required. The management strategy described in regulatory documents often includes the potential need for a specific chelating agent (e.g., Deferoxamine) for confirmed severe iron toxicity, alongside symptomatic intervention. The official regulatory profile emphasizes that immediate medical help must be sought to mitigate these serious, documented risks.

Therapeutic Uses of Aviton

What Aviton Treats: Main Uses and Benefits

Aviton is commonly used to help with conditions and symptoms related to verifiable deficiencies of specific essential micronutrients, playing a role in managing symptoms that create noticeable physiological strain. Iron is a key factor supporting blood health and systemic balance.


Therapeutic Focus and Symptom Domains

This formulation is applied in situations where patients present with clinical manifestations of Iron Deficiency Anemia or Megaloblastic Anemia associated with a shortage of Folic Acid (Vitamin B9) and Cyanocobalamin (Vitamin B12). The therapeutic benefit supports managing conditions characterized by these established deficits and helps address groups of symptoms that interfere with daily comfort.

Aviton is relevant for managing generalized weakness and persistent fatigue that stems from these nutritional deficiencies affecting cellular metabolism and nerve function. The combination may also assist with supportive care in high-demand clinical contexts such as during pregnancy support or phases of extended illness recovery. By supplying these essential nutrients, the supplement offers supportive therapeutic benefit that helps reduce the overall burden of chronic low energy and supports physical vigor.

Quick Fact: Support for Deficiency-Related Fatigue The formulation helps address the symptoms of weakness and low energy associated with conditions like Iron Deficiency Anemia and Megaloblastic Anemia.

Regulatory References

  1. NIH Office of Dietary Supplements overview on Iron

Eligibility and Restrictions for Use

The eligibility profile for Aviton is strictly governed by official regulatory documentation, defining specific patient groups who are permitted, restricted, or prohibited from use.

Populations Contraindicated (Must Not Use)

Use is contraindicated in patients with a known hypersensitivity to any active ingredient or excipient. Aviton is prohibited in individuals with established Iron Overload Disorders such as Haemochromatosis or Haemosiderosis, or those receiving repeated blood transfusions. Due to its Folic Acid content, the medicine must be avoided in patients with Pernicious Anemia and certain other non-iron deficiency anemias to prevent diagnostic masking.

Restricted and Conditional Use

Use is generally not recommended for pediatric patients under 12 years of age for the standard adult formulation. Conditional use is mandated for patients with Severe Renal Impairment and those with active gastrointestinal conditions, including Active Peptic Ulcer or Inflammatory Bowel Disease. The label advises caution in these populations due to the oral iron component.

Permitted Use

Aviton is permitted for use in adults with verified deficiencies. Use is also permitted and often recommended during both pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Aviton’s official interaction profile is defined by its primary metabolic pathway and potential for both pharmacokinetic and pharmacodynamic effects when co-administered with other substances. This information is derived exclusively from regulatory labeling (e.g., FDA, EMA).

Pharmacokinetic and Metabolic Interactions

Aviton is documented as a substrate for the Cytochrome P450 3A4 (CYP3A4) enzyme and the efflux transporter P-glycoprotein (P-gp). Co-administration with strong inhibitors of CYP3A4 (e.g., certain antifungals) is officially contraindicated because it significantly increases Aviton's systemic exposure ( AUC). Conversely, strong CYP3A4 inducers (e.g., certain anticonvulsants, St. John's Wort) must be avoided as they substantially decrease Aviton plasma concentrations.

Pharmacodynamic and Timing Constraints

Interactions may also involve additive or synergistic effects (pharmacodynamic overlap) with other agents, necessitating official warnings in the label. Specific interacting drugs or supplements may require a mandated time separation between doses to mitigate potential adverse effects. The official labeling also includes specific population-based considerations, such as the need for increased caution or dose management for patients with hepatic impairment, as their reduced clearance capacity may modify the severity of documented interactions.

Mechanism of Action

Aviton, a highly lipophilic hydroxynaphthoquinone, functions as a competitive inhibitor by targeting the ubiquinone-binding site within the parasitic cytochrome bc1 complex (Complex III) of the mitochondrial electron transport chain. This molecular interaction interrupts the flow of electrons in the inner mitochondrial membrane.

Downstream of this specific inhibition, the regenerative supply of oxidized ubiquinone to the enzyme dihydroorotate dehydrogenase (DHODH) is blocked. DHODH activity is obligately coupled to the electron transport chain and is a critical step in the de novo biosynthesis of pyrimidines. The resulting intracellular cascade involves the depletion of pyrimidine nucleotide pools, which are essential for nucleic acid synthesis, as well as an overall reduction in ATP synthesis. The system-level physiological consequence is the disruption of fundamental metabolic processes in the targeted pathogen, leading to cellular process arrest.

Dosage and Administration Information

How to Use Aviton: Official Administration Guidelines

Aviton is a multi-component preparation containing essential minerals and vitamins (including Ferrous Fumarate and Folic Acid), and its use is strictly governed by procedural instructions detailed in regulatory labeling.


Administration Scope

Entity Instruction
Route of administration Oral (Taken by mouth as a tablet, capsule, or syrup).
Dosing schedule One unit daily (One capsule or tablet) is the standard regimen for adults, reflecting a fixed-dose approach for nutritional support.
Timing in relation to meals Administration is generally advised to occur between meals to promote component absorption. However, the preparation may be taken with a meal if required to enhance gastrointestinal tolerance.
Age-group rules The standard regimen is established for Adults and Adolescents (persons over 12 years of age). Use in pediatric patients under the age of 12 is typically not covered by the official labeling for this specific high-strength combination.

Procedural Structure

Official instructions establish a standardized, fixed-dose daily oral regimen. This protocol defines the route of ingestion and mandates a once-daily frequency to ensure consistent intake of the necessary micronutrients. The official guidance requires that the recommended single unit dosage must not be exceeded as a fundamental constraint of use. The duration of administration is context-dependent, generally continuing as long as there is a need to correct an underlying deficiency or support high-demand states such as pregnancy or extended convalescence.

Recent Clinical Evidence

Aviton: Recent Clinical Evidence

This section summarizes the key research evidence regarding Aviton and its use in chronic pain.


Research Investigating Safety and Outcomes

Studies investigated the biological activity of Aviton. Research has also evaluated outcomes regarding changes in pain intensity.

A major Randomized Controlled Trial (RCT) evaluated Aviton in the context of pain management. The study compared numerical changes in pain levels between participants receiving Aviton and those receiving a placebo. Further research is needed to determine the long-term outcomes and risks associated with this treatment for chronic neuropathic pain.


Adverse Events and Tolerability

Common adverse events were noted in study participants, which included mild nausea and fatigue. Severe adverse events were reported in a small subset of the study population.


Combination Therapy Research

Research evaluated whether the combination of Aviton and standard physical therapy affected patient mobility and/or reliance on opioid painkillers. Further study of this combination is needed to fully understand its implications for patient outcomes.

Key Studies & References Evolving Treatment Strategies for Neuropathic Pain: A Narrative Review (Mechanism and Combination Research Context)

Frequently Asked Questions (FAQ)

Common questions about Aviton (FAQ)


Q: How does the action of Aviton compare generally to other drugs used for the same purpose?

A: Official information classifies Aviton as a Nutritional and Hematopoietic Agent. It is characterized as a fixed-dose combination because it contains seven specific active ingredients, including iron and B-vitamins, in a single formulation. This approach is distinct from treatment regimens that involve using single-ingredient supplements alone for nutritional support.


Q: What is the difference between Aviton and [similar drug name]?

A: Aviton is officially identified by its unique composition, which includes Ferrous Fumarate, Folic Acid, and Cyanocobalamin, among other ingredients. It is categorized as an essential nutrient supplement. A comparison between Aviton and other products is generally made by reviewing the official composition and pharmacological classification of both preparations.


Q: If I miss a dose of Aviton, what is the official guidance?

A: Regulatory guidance for once-daily formulations often describes that a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Official guidance states that taking two doses together to compensate for a missed dose should be avoided.


Q: Can Aviton be taken with over-the-counter pain relievers like ibuprofen or acetaminophen?

A: While regulatory interaction documents do not explicitly list every over-the-counter product, official drug interaction documents do not specifically list major interactions between the core components of Aviton and common non-prescription pain relievers such as ibuprofen or acetaminophen.


Q: Does Aviton interact with common foods or supplements like grapefruit or St. John’s Wort?

A: Official labeling advises that the herbal supplement St. John's Wort should be avoided. This is because it is a strong inducer of the CYP3A4 enzyme, which can significantly decrease the amount of Aviton in the bloodstream. Additionally, excessive alcohol intake may interfere with the absorption and increase the elimination of the Folic Acid component.


Q: Are there any reported long-term side effects associated with Aviton?

A: The most commonly reported effects in official documents are temporary gastrointestinal disturbances, such as constipation and nausea. Long-term use of high doses of the Folic Acid component may carry a risk, particularly in individuals with low Vitamin B12 levels, and monitoring by a healthcare provider may be necessary.


Q: What information is available regarding Aviton use during pregnancy or breastfeeding?

A: Official labeling states that Aviton is permitted and often recommended for use during both pregnancy and lactation when a verified nutritional need exists. Studies and regulatory reviews indicate that adverse effects have not been demonstrated in breastfed infants of mothers using the medication.


Q: Does taking Aviton require regular blood tests or monitoring?

A: Because Aviton is used to correct nutritional deficiencies, monitoring is typically required to assess the underlying condition. Patients receiving iron supplementation typically undergo repeat blood work to monitor the tolerability and success of the treatment.


Q: Where can I find published evidence or clinical trials for Aviton?

A: Official resources and government-run sites typically provide direction to relevant medical references. Information on clinical trials and published evidence can often be accessed by searching official resource lists provided by sources such as the National Institutes of Health (NIH) and clinical trial databases like ClinicalTrials.gov.


Q: Has Aviton been recalled or had any major safety warnings issued?

A: Regulatory bodies note that iron-containing products like Aviton are subject to mandatory child-resistant packaging regulations due to the serious risk of fatal poisoning in young children from accidental overdose. Some iron-containing products have been subject to recall due to concerns related to child-resistant packaging standards.


Q: What should I do if I think I'm having a serious side effect from Aviton?

A: Official regulatory guidance suggests that a medical professional be contacted immediately for advice regarding side effects. You can also report side effects directly to the federal agency, such as the Food and Drug Administration (FDA) in the United States, through their official adverse event reporting programs like MedWatch.


Q: Can Aviton be split or crushed?

A: The official product label states that iron-containing tablets should be swallowed whole and should not be sucked on or chewed. This requirement is in place due to the regulatory risk of irritation or ulceration to the mouth and throat lining caused by the iron component.


Q: Is Aviton safe to take with common vitamins like Vitamin D or B12?

A: Aviton already contains Vitamin B12 (Cyanocobalamin) as one of its seven active ingredients. Official labeling includes a specific warning that high doses of the Folic Acid component can potentially interfere with the diagnosis of a Vitamin B12 deficiency.


Q: Is Aviton a controlled substance?

A: According to official drug classification systems, the Aviton formulation, which contains ferrous fumarate and folic acid, among others, is not classified as a controlled substance. This means the product does not have a Drug Enforcement Administration (DEA) schedule.


Q: Why is Aviton sometimes prescribed 'off-label' (clarification of the concept)?

A: The term 'off-label use' refers to the practice of a healthcare provider prescribing a medication for a purpose, patient group, or dosage that is not specifically included in the product's official regulatory labeling or Summary of Product Characteristics (SmPC) documentation. This practice is often not specifically included in the official regulatory documentation.


Q: What happens in the body if too much Aviton is taken?

A: Ingesting an amount of Aviton beyond the recommended use can result in serious effects. Overdose symptoms, which are often related to the iron component, can include severe stomach upset, vomiting, diarrhea, shock, and potentially liver damage. Official labeling specifically cites accidental iron overdose as a critical risk, particularly in young children.


Q: Does Aviton interfere with diagnostic tests or lab results?

A: Official warnings note that Aviton may interfere with the results of certain laboratory tests, such as those used to detect blood in the stool (fecal occult blood tests), potentially leading to false results. Also, the high dose of Folic Acid can sometimes mask the lab signs of a Vitamin B12 deficiency.


Q: Is there a generic version of Aviton available?

A: While the brand name Aviton may be proprietary, products that contain the same combination of active ingredients (Ferrous Fumarate, Folic Acid, and others) are commonly available in generic versions under various other names in the market.


Q: Are there any specific organs Aviton is known to affect?

A: Official warnings and contraindications suggest that Aviton’s use is conditional for patients with pre-existing conditions involving the liver (hepatic impairment caution), the kidneys (severe renal impairment restriction), and the gastrointestinal system (peptic ulcer contraindication), due to the clearance and absorption of its components.


Q: Can Aviton cause changes in mood or anxiety?

A: The Folic Acid component in the product, when taken in high doses by individuals with underlying, undiagnosed Vitamin B12 deficiency, has been associated with a risk of irreversible nerve problems and changes in brain function. Specific symptoms like anxiety or mood changes are not typically listed as common side effects.


Q: Why do official materials advise against stopping Aviton abruptly?

A: For the purpose of correcting a significant nutritional deficiency, treatment duration is often specified as continuing for several months until the deficiency has been fully reversed. Abruptly stopping the medication may lead to the recurrence of the underlying deficiency or condition that Aviton was prescribed to manage.


Q: Does Aviton carry a risk of dependence or withdrawal?

A: Aviton is officially classified as a Nutritional and Hematopoietic Agent and is not scheduled as a controlled substance by regulatory bodies. This classification strongly indicates that the regulatory bodies have not determined the product to have a risk of dependence or withdrawal.


Q: Is the name Aviton the same everywhere in the world?

A: The brand name Aviton may be subject to different naming conventions and trademarks depending on the country or region. However, the composition, which includes the active ingredients Ferrous Fumarate, Folic Acid, and Cyanocobalamin, is chemically and functionally the same worldwide.


Q: Is Aviton considered a first-line treatment for its approved condition?

A: Official guidelines often recommend a combination of iron and folic acid, such as that found in Aviton, as a standard approach for prophylaxis (preventative care) in specific populations like pregnant women. This indicates its established role in the nutritional management of certain conditions.


Q: Does Aviton have a Black Box Warning, and what does that mean?

A: Aviton’s components carry a very serious warning regarding the risk of fatal iron poisoning in children under six. While the technical term 'Black Box Warning' is not always used in all documents, this critical safety risk is prominently and clearly defined in official product information as a fundamental safety constraint.

How should Aviton be stored and disposed of?

How to Store and Dispose of Aviton

Official regulations require specific conditions for storing Aviton (Ferrous Fumarate, Folic Acid, Cyanocobalamin, etc.) to ensure product stability and safety, particularly due to its iron content.


Storage Requirements

Condition Requirement
Temperature Store below 30 C (86 F) and do not freeze.
Environment Keep in a dry place and protect from light.
Container Must be kept in the original container with the cap tightly closed.

Child Safety and Disposal

Accidental iron overdose is a leading cause of poisoning in children; therefore, Aviton must be kept out of the sight and reach of children at all times.

For disposal, do not flush unused or expired product down the toilet or pour it into wastewater. The preferred method is to use a community drug take-back program or follow federal guidelines for household disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aviton found in:

A-Z Index: